跳转至内容
Merck
CN

B5016

Sigma-Aldrich

苄普地尔 盐酸盐

calcium channel blocker, powder

别名:

1-异丁氧基-2-吡咯烷基-3-（N-苄基苯胺）丙烷 盐酸盐

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C24H34N2O · HCl
化学文摘社编号:
68099-86-5
分子量:
403.00
MDL编号:
MFCD00065498
UNSPSC代码:
12352202
PubChem化学物质编号:
24277824
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

苄普地尔 盐酸盐, powder

表单

powder

质量水平

100

创始人

Johnson & Johnson

SMILES字符串

Cl.CC(C)COCC(CN(Cc1ccccc1)c2ccccc2)N3CCCC3

InChI

1S/C24H34N2O.ClH/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22;/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3;1H

InChI key

JXBBWYGMTNAYNM-UHFFFAOYSA-N

基因信息

human ... CACNA1A(773), CACNA1B(774), CACNA1C(775), CACNA1D(776), CACNA1E(777), CACNA1F(778), CACNA1G(8913), CACNA1H(8912), CACNA1I(8911), CACNA1S(779), CACNA2D1(781), CACNA2D2(9254), CACNA2D3(55799), CACNA2D4(93589), CACNB1(782), CACNB2(783), CACNB3(784), CACNB4(785), CACNG1(786), CACNG2(10369), CACNG3(10368), CACNG4(27092), CACNG5(27091), CACNG6(59285), CACNG7(59284), CACNG8(59283)

相关类别

生化/生理作用

非选择性钙通道阻滞剂和 IV 类抗心律失常药；抑制Na+-Ca2+ 交换；体外抑制脑肿瘤细胞的生长。

特点和优势

该化合物由 Johnson & Johnson 开发。如需浏览其他制药公司开发的化合物和批准的药物/候选药物列表，请点击此处。

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
BCCL3334
BCCL0614
BCCH8357
BCCF3417
BCCB4077

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Chikako Shimizu et al.
Biological & pharmaceutical bulletin, 41(7), 1049-1061 (2018-05-18)
Ethanol (EtOH) dosage, frequency, and paired associative learning affect the risk of alcoholism. Recently, Spanagel et al. reported that acamprosate calcium (Acam Ca) prescribed for alcoholism exerts an anti-relapse effect via Ca. Ca is contained in foods, sometimes consumed with
Juliana Q Reimão et al.
Experimental parasitology, 128(2), 111-115 (2011-03-01)
The need for novel and efficacious drugs against neglected parasitic diseases, such as Leishmaniasis and American Trypanosomiasis, is certainly apparent. In this work, we evaluated the in vitro potential of the calcium channel blocker bepridil against Leishmania spp. and Trypanosoma
Tsuyoshi Shiga et al.
Circulation journal : official journal of the Japanese Circulation Society, 75(6), 1334-1342 (2011-04-13)
It is unknown whether bepridil improves cardiovascular events in atrial fibrillation (AF) patients, so this study evaluated the clinical outcome in paroxysmal or persistent AF patients receiving bepridil. We conducted a cohort study of 284 consecutive patients who received bepridil
Masato Murakami et al.
Journal of cardiovascular pharmacology, 56(4), 389-395 (2010-07-14)
It has been reported that bepridil prevents ventricular fibrillation (VF) in patients with Brugada syndrome, but the comparative efficacy with and without mutation in the SCN5A gene has not been elucidated. The purpose of this study was to assess the
Hiroki Takanari et al.
Journal of pharmacological sciences, 115(1), 15-26 (2010-12-16)
Bepridil is effective for conversion of atrial fibrillation to sinus rhythm and in the treatment of drug-refractory ventricular tachyarrhythmias. We investigated the effects of bepridil on electrophysiological properties and spiral-wave (SW) reentry in a 2-dimensional ventricular muscle layer of isolated
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持